Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qianhai Health Holdings Limited 前海健康控股有限公司

(incorporated in the Cayman Islands with limited liability) (Stock Code: 911)

(1) CLARIFICATION ON MAJOR TRANSACTION ANNOUNCEMENT; AND (2) CLARIFICATION ON PROFIT WARNING ANNOUNCEMENT

References are made to the (i) announcement (the "Major Transaction Announcement") of Qianhai Health Holdings Limited (the "Company") dated 19 August 2021 in relation to, among others, the major transaction; and (ii) announcement (the "Profit Warning Announcement", together with the Major Transaction Announcement, the "Announcements") of the Company dated 10 August 2021 in relation to the financial performance of the Group for the six months ended 30 June 2021 (the "2021 Interim Period"). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcements.

CLARIFICATION ON THE MAJOR TRANSACTION ANNOUNCEMENT

As disclosed in the Major Transaction Announcement, as at the date thereof, the shareholding in the Target Company has not been transferred from the Vendor to the Purchaser. The Board wishes to inform the shareholders and potential investors of the Company that, on 24 August 2021, the Company was informed by Mr. Huang, a non-executive Director, that the Vendor first signed the instrument of transfer regarding the transfer of shareholding in the Target Company and passed it on to the Purchaser, which subsequently signed and dated the same. The duly executed instrument of transfer dated 6 January 2021 was only located by Mr. Huang and passed to the Board subsequent to the date of the Major Transaction Announcement. As a result, the Board wishes to clarify that the transfer of shareholding of the Target Company has become effective on 6 January 2021, and the Target Company, QHIL and Zhejiang Huijun had ceased to be subsidiaries of the Company, and their financial statements had also ceased to be consolidated into the Group's financial statements. In addition, the Group no longer held any equity interests in Zhongan Huijun from 6 January 2021, and its performance should no longer be reflected in the share of results of joint venture of the Company since then.

CLARIFICATION ON THE PROFIT WARNING ANNOUNCEMENT

As a result of the foregoing, the Board wishes to further clarify the increase of share of loss of a jointly venture entity, which engaged in joint development of a land parcel in China, as disclosed in the Profit Warning Announcement, did not attribute to the Group's net loss for the 2021 Interim Period.

As the Company is still in the process of finalising the unaudited consolidated results for the 2021 Interim Period, the Board wishes to inform the shareholders and potential investors of the Company that the Company is in the course of (i) assessing the impact of the Disposal on the unaudited consolidated results for the 2021 Interim Period; and (ii) estimating impairment loss under the expected credit loss model on the trade receivables. The Company will make further announcement regarding the unaudited consolidated results for the 2021 Interim Period as and when appropriate. Further details of the Group's financial results and performance will be disclosed in the Company's interim results announcement which is expected to be published by the end of August 2021 in accordance with the requirements of the Listing Rules.

Save for the above clarifications, all other information and content of the Announcements remain unchanged.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Qianhai Health Holdings Limited Huang Guanchao Chairman

Hong Kong, 25 August 2021

As at the date of this announcement, the non-executive Directors are Mr. Huang Guanchao and Mr. Lim Tzea; the executive Directors are Mr. Xu Keli and Mr. Lam Hin Chi and the independent non-executive Directors are Mr. Li Wei, Mr. Wu Wai Leung Danny and Mr. Yuen Chee Lap Carl.